(6-(aminomethyl)pyridin-3-yl)methanamine | 90008-38-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (6-(aminomethyl)pyridin-3-yl)methanamine
• 英文别名: 2,5-Pyridinedimethanamine；[6-(aminomethyl)pyridin-3-yl]methanamine
• CAS: 90008-38-1
• 化学式: C₇H₁₁N₃
• 分子量: 137.184
• InChiKey: CBRAMLKUPIVRPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-2-(5-amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-2-phenylpropanoic acid 、 (6-(aminomethyl)pyridin-3-yl)methanamine 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以63%的产率得到
  参考文献：
  名称：

  WO2019196803A5

  摘要：

  公开号：

  WO2019196803A5

文献信息

• [EN] BENZYLAMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZYLAMINE
  申请人：KALVISTA PHARMACEUTICALS LTD

  公开号：WO2014108679A1

  公开（公告）日：2014-07-17

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

  本发明提供了化合物的公式(I)：包含这种化合物的组合物；在治疗中使用这种化合物（例如在涉及血浆激肽酶活性的疾病或病况的治疗或预防中）；以及使用这种化合物治疗患者的方法；其中R1至R3，R5至R9，A，P，V，W，X，Y和Z如本文所定义。
• FRICTIONLESS MOLECULAR ROTARY MOTORS
  申请人：Keinan Ehud

  公开号：US20100016610A1

  公开（公告）日：2010-01-21

  A rotaxane consisting of a cucurbituril and an uncharged guest molecule, having low or null affinity therebetween is provided as well as processes for providing the same. Various uses as energy converters (“frictionless” molecular motors), biochips and biosensors using the same are also provided.

  提供了由葫芦醚和一个不带电的客体分子组成的轮烷，并提供了它们之间具有低或无亲和力的过程。还提供了使用这种轮烷作为能量转换器（“无摩擦”分子马达）、生物芯片和生物传感器的各种用途。
• Novel 2-pyridinecarboxamide derivatives
  申请人：Mitsuya Morihiro

  公开号：US20060258701A1

  公开（公告）日：2006-11-16

  The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，具有激活葡萄糖激酶的效果，并可用作糖尿病治疗剂，其化学式表示为（I）：[其中X1表示氮原子、硫原子、氧原子或类似物；R1表示6-至10-成员芳基基团、5-至7-成员杂芳基基团或类似物；D表示氧原子或硫原子；R和R3相同或不同，分别表示氢原子、低碳基或类似物；式（II）表示可选取代的5-至7-成员杂芳基团或类似物；式（III）表示单环或双环杂芳基团]或其药学上可接受的盐。
• NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES
  申请人：MITSUYA MORIHIRO

  公开号：US20100041660A1

  公开（公告）日：2010-02-18

  The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R 2 and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.

  本发明涉及一种具有葡萄糖激酶激活作用并且可用作糖尿病治疗剂的化合物，其化学式为（I）：[其中X1代表氮原子、硫原子、氧原子或类似物；R1代表6到10个成员的芳基基团、5到7个成员的杂芳基团或类似物；D代表氧原子或硫原子；R2和R3相同或不同，每个代表氢原子、低碳基团或类似物；化学式（II）代表可选取代的5到7个成员的杂芳基团或类似物；化学式（III）代表单环或双环杂芳基团]或其药学上可接受的盐。
• BENZYLAMINE DERIVATIVES
  申请人：KALVISTA PHARMACEUTICALS LIMITED

  公开号：US20160039752A1

  公开（公告）日：2016-02-11

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

  本发明提供了式(I)的化合物：包括这些化合物的组合物；使用这些化合物进行治疗（例如在涉及血浆卡利肌酶活性的疾病或病症的治疗或预防中）；以及使用这些化合物治疗患者的方法；其中R1至R3，R5至R9，A，P，V，W，X，Y和Z的定义如本文所述。